1,5,13,17-tetrakis(tert-butoxycarbonyl)-1,5,13,17-tetraazaheptadecane | 131275-10-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1,5,13,17-tetrakis(tert-butoxycarbonyl)-1,5,13,17-tetraazaheptadecane
• 英文别名: 1,5,13,17-tetra(t-butoxycarbonyl)-1,5,13,17-tetraazaheptadecane；tert-butyl N-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propyl]-N-[7-[(2-methylpropan-2-yl)oxycarbonyl-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propyl]amino]heptyl]carbamate
• CAS: 131275-10-0
• 化学式: C₃₃H₆₄N₄O₈
• 分子量: 644.893
• InChiKey: PUWRRRJVVWDEBA-UHFFFAOYSA-N

物化性质

• 沸点：
  699.9±55.0 °C(Predicted)
• 密度：
  1.040±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  45
• 可旋转键数：
  24
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  136
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  1,5,13,17-tetrakis(tert-butoxycarbonyl)-1,5,13,17-tetraazaheptadecane 生成 N,N'-二(3-乙基氨基丙基)庚烷-1,7-二胺
  参考文献：
  名称：

  Use of N,N'-bis 3-(ethylamino)propyl -1,7-heptanediamine and a cytotoxic agent

  摘要：

  本发明涉及将N,N'-双[3-(乙基氨基)丙基]-1,7-庚二胺与从抗肿瘤韦因卡生物碱、抗肿瘤抗生素、抗肿瘤抗代谢物和抗肿瘤铂配合物中选择的细胞毒性药物结合，用于制备一种药物组合物，可用于治疗患有肿瘤疾病状态的患者。

  公开号：

  EP0490380A2
• 作为产物：
  描述：

  3-[7-(2-Cyanoethylamino)heptylamino]propanenitrile 在 platinum(IV) oxide 盐酸 、 sodium hydroxide 、 氢气 、 溶剂黄146 作用下， 以 四氢呋喃 为溶剂， 生成 1,5,13,17-tetrakis(tert-butoxycarbonyl)-1,5,13,17-tetraazaheptadecane
  参考文献：
  名称：

  Antimalarial polyamine analogs

  摘要：

  A series of novel tetraamines of the general formula RNH(CH2)(x)NH(CH2)(y)(NH(CH2)(x)NHR was synthesized and examined for activity against growth of Plasmodium falciparum in vitro. Within the series, dibenzyl analogues (R = benzyl) were found to be the most effective growth inhibitors, with IC50 values of about 10-6 M. Further modifications of the tetraamine provided the optimum chain length for antimalarial activity of y = 7, x = 3. Compound 8 (MDL 27,695) with the structure y = 7, x = 3, R = benzyl, in combination with the ornithine decarboxylase inhibitor alpha-(difluoromethyl)ornithine, resulted in radical cures when tested against experimental Plasmodium berghei infections in mice. The structure-activity relationships of the series are discussed.

  DOI：

  10.1021/jm00106a015

文献信息

• Polyamine derivatives as antineoplastic agents
  申请人：Merrell Dow Pharmaceuticals Inc.

  公开号：US05109024A1

  公开（公告）日：1992-04-28

  The present invention relates to certain novel polyamine compounds of the formula: ##STR1## wherein Z is a saturated (C.sub.2 -C.sub.6) alkylene moiety, each R group independently is hydrogen, methyl, ethyl, or n-propyl with the provisos that both R groups cannot be hydrogen and that R is hydrogen or methyl when Z is a branched chain alkylene; or a pharmaceutically acceptable acid addition salt thereof.

  本发明涉及某些新型聚胺化合物，其化学式为：##STR1## 其中Z是饱和的（C.sub.2-C.sub.6）烷基亚甲基，每个R基独立地是氢、甲基、乙基或正丙基，但是有以下限制：两个R基不能都是氢，当Z是支链烷基时，R是氢或甲基；或其药学上可接受的酸盐。
• Method of treating cancer by conjunctive therapy with
  申请人：Merrell Pharmaceuticals Inc.

  公开号：US05561136A1

  公开（公告）日：1996-10-01

  The present invention relates to a method of treating a patient suffering from a neoplastic disease state comprising administering to said patient an effective antineoplastic amount of N,N'-bis[3-(ethylamino)propyl]-1,7-heptanediamine in conjunctive therapy with an effective antineoplastic amount of a cytotoxic agent selected from the group consisting of an antineoplastic vinca alkaloid, an antineoplastic antibiotic, an antineoplastic antimetabolite and an antineoplastic platinum coordination complex, wherein a synergistic antineoplastic effect results.

  本发明涉及一种治疗患有肿瘤疾病状态的患者的方法，包括向该患者施用有效的抗肿瘤剂量的N,N'-双[3-(乙基氨基)丙基]-1,7-庚二胺，与有效的抗肿瘤剂量的细胞毒性药物共同治疗，所述细胞毒性药物选自抗肿瘤长春花生物碱、抗肿瘤抗生素、抗肿瘤类似物和抗肿瘤铂配合物组，从而产生协同的抗肿瘤效应。
• EDWARDS, M. L.;STEMERICK, D. M.;BITONTI, A. J.;DUMONT, J. A.;MCCANN, P. P+, J. MED. CHEM., 34,(1991) N, C. 569-574
  作者：EDWARDS, M. L.、STEMERICK, D. M.、BITONTI, A. J.、DUMONT, J. A.、MCCANN, P. P+

  DOI：——

  日期：——
• POLYAMINE DERIVATIVES AS ANTI-CYTOMEGALOVIRAL AGENTS
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0662829A1

  公开（公告）日：1995-07-19
• US5109024A
  申请人：——

  公开号：US5109024A

  公开（公告）日：1992-04-28